The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
PARP inhibitors (PARPi) have shown promising clinical results and have revolutionized the landscape of ovarian cancer management in the last few years. While the core mechanism of action of these drugs has been largely analyzed, the interaction between PARP inhibitors and the microenvironment has be...
Main Authors: | Margherita Turinetto, Giulia Scotto, Valentina Tuninetti, Gaia Giannone, Giorgio Valabrega |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.689829/full |
Similar Items
-
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
by: Margherita Turinetto, et al.
Published: (2022-03-01) -
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
by: Gaia Giannone, et al.
Published: (2022-05-01) -
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
by: Gaia Giannone, et al.
Published: (2020-06-01) -
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
by: Giulia Scotto, et al.
Published: (2021-12-01) -
Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
by: Francesca Arezzo, et al.
Published: (2024-01-01)